Gilead’s Dietmar Berger Reflects On Pipeline After First Year As CMO

Beyond HIV In Virology, New Modalities In Cancer

 
• By Mandy Jackson
  
Gilead has several HIV and cancer milestones ahead in 2026 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business